Browse by author
Lookup NU author(s): Dr Helen Robertson,
Emeritus Professor John Kirby,
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Background. Chronic rejection is a major cause of graft dysfunction after kidney transplantation. This fibroproliferative disease may be promoted by overproduction of transforming growth factor beta (TGF-β). Previous studies have suggested that CsA might increase production of this growth factor. The current study was designed to measure the expression of TGF-βb in renal transplant biopsy specimens from patients undergoing immunosuppressive therapy with either CsA or tacrolimus (FK506). Method. Paraffin-embedded renal biopsy specimens were sectioned, dewaxed, and incubated with primary antibody against TGF-βb1 latency-associated protein and active TGF-βb1. After washing, the sections were treated with secondary antibody conjugated with FITC. In each case, the sections were assessed by semiquantitative scanning laser confocal microscopic method. Results. There was no significant difference in latent TGF-βb expression between biopsy specimens from patients receiving CsA and patients receiving FK506. However, biopsy specimens from patients receiving CsA expressed significantly more active TGF-βb1 than biopsy specimens from patients receiving FK506 (P<0.0001, Mann-Whitney test). Discussion. The increased level of active TGF- β1 expression in renal biopsy specimens of patients receiving CsA may indicate a mechanism of chronic rejection. However, these biopsies were performed to assess deranged renal function; therefore, the specimens may reflect events rather than differences in medication.
Author(s): Kirby JA; Robertson H; Talbot D; Mohamed MAS; Booth TA; Balupuri S
Publication type: Article
Publication status: Published
ISSN (print): 0041-1337
ISSN (electronic): 1534-6080
Publisher: Lippincott Williams & Wilkins
PubMed id: 10755567
Altmetrics provided by Altmetric